Proclarix

Indicaton

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Therapeutic indications

Type of product

Diagnostic

Table

Phase

Marketed
Available in

EU, Switzerland

You may also be interested in

Dimiracetam

Management of acute and chronic symptoms of chemotherapy-induced sensory peripheral neuropathy.

Phase II started

Small molecule therapeutic that aims to treat Alzheimer’s patients

Alzheimer’s disease

Discovery

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening.
The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases.
Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed

Proclarix

Proclarix

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

Dimiracetam

Small molecule therapeutic that aims to treat Alzheimer’s patients

Breast cancer screening test